Clinical trial · Interventional
PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy With or Without Panitumumab as First-line Treatment of Subjects With Metastatic or Recurrent Head and Neck Cancer, and Cross-over Second-line Panitumumab Monotherapy of Subjects Who Fail the Combination Chemotherapy…
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a randomized, open-label, 2-arm, controlled, phase 2, multi-center, estimation clinical trial of docetaxel and cisplatin combination chemotherapy with and without panitumumab in the first-line treatment of subjects with metastatic or recurrent head and neck cancer, as well as a cross-over second-line panitumumab monotherapy of subjects who fail the chemotherapy only arm. This study will be conducted in the United States. Approximately 150 subjects with histologically or cytologically confirmed metastatic and/or recurrent SCCHN.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cisplatin | Drug | Cisplatin | ALIAS |
| Docetaxel | Drug | Docetaxel | ALIAS |
| Panitumumab | Drug | Panitumumab | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm 1
- description
- Panitumumab + Docetaxel + Cisplatin
- interventionNames
- Drug: Panitumumab
- Drug: Cisplatin
- Drug: Docetaxel
- type
- OTHER
- label
- Arm 2
- description
- control
- interventionNames
- Drug: Cisplatin
- Drug: Docetaxel
Primary outcomes (1)
- measure
- Progression Free Survival (PFS) During the First-line Treatment Phase
- timeFrame
- Every 6 weeks until disease progression or death, up to 67 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically confirmed metastatic and/or recurrent Squamous Cell Carcinoma of Head and Neck (SCCHN) determined to be incurable by surgery and/or radiation therapy. * Measurable disease by CT scan * Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 * Age: 18 years or older * Adequate hematologic, renal, metabolic, hepatic \& thyroid function Exclusion Criteria: * Prior systemic treatment for metastatic and/or recurrent SCCHN * CNS metastases, or nasopharyngeal carcinoma * History of interstitial lung disease * History of another primary cancer * Any co-morbid disease that would increase risk of toxicity * Active infection requiring systemic treatment * Prior anti-Epidermal Growth Factor receptor (anti-EGFr) antibody therapy
References
Publications (1)
- BACKGROUNDWirth LJ. PARTNER: a study of panitumumab plus chemotherapy for first-line treatment of advanced head and neck cancer. Commun Oncol. 2008;5(Supp 14):1-4.